Gelonghui, April 5, 丨 Changjiang Life Technology (00775.HK) announced that the company will present two sets of new pre-clinical research data on rat sarcoma virus cancer gene (KRAS) and cytostatic death-ligand 1 (PD-L1) research cancer vaccines at the 2024 annual meeting of the American Association for Cancer Research (AACR) to be held in San Diego, California, USA.
According to the disclosure, KRAS protein is commonly mutated in various cancers and is a key regulator of cell growth and survival, driving tumor growth by promoting uncontrolled cell reproduction and resistance to treatment. PD-L1 protein is one of the most important immune checkpoint proteins. It is highly present in cancer cells and can limit T cell activation in the tumor microenvironment.
In pre-clinical research, the company investigated whether the KRAS polypeptide cancer vaccine and the novel synthetic long peptide vaccine targeting multiple PD-L1T cell antigen determinants can induce significant anti-tumor efficacy in homologous mouse colorectal cancer models.
Additionally, the company, together with its research partner XtalPi (XtalPi), will present data on its artificial intelligence (AI) enabling platform for designing cancer vaccines at the AACR 2024 annual meeting. The company and XtalPi discovered that the AI model developed in their research collaboration can significantly improve the design of novel antigen peptide vaccines, and is superior to the most advanced prediction algorithms in predicting the presentation of MHC-I and MHC-II antigens.
The company believes that the preclinical efficacy results of the investigational cancer vaccine against KRAS and PD-L1 protein are encouraging, and the company hopes to advance these vaccines and other vaccines to the clinical research stage in the future. The company is also pleased with the progress of the research collaboration with XtalPi. The AI platform developed by this collaborative project aims to help predict immunogenicity more accurately and design or more effective cancer vaccines.